I topped up today - but sadly not 594k 😂 |
594k buy!!!!!!!!!!!!!!!!!!!!!!!!
hence that sudden reversal.
Surely they can't know anything......
rns or noos tomorrow and it'd look a tad suss. |
Constellation Mapped Read Technology |
A few tightly wound bulls and bears on here.
About a penny to go. Volume pants so might struggle as sellers appear to be almost done. that's not gonna go down well with the 'placing tomorrow' contingent.
ILMN share price under pressure. Been in an horrendous downtrend for the last 4 years so needs a win.
edit; nice bounce. Does it have legs.... The christy turlington would be nice. |
 Bones,
Just to be clear, they do not need to have sufficient funds for the next twelve months - they need to have the reasonable belief that they will be able to secure the same. There is a difference.
There has been a bout of profit taking and that is not unreasonable. I opined previously that another placing at some point is likely and not an existential threat at this point. You see, news on both Astra and Eisai could land at any point and that alters the state of affairs, as does any partnership news with Illumina and/or others.
Clearly there is a risk of a failure to secure deals offset by the potential upside form announcement of one or more of those. That is the balance that needs to be struck here, not simply shouting placing without any context as you appear to be doing, or worse still, offerings from single digit IQ Patt in which the same guff is reproduced tirelessly thinking it is analysis.
I welcome bearish views, but these should be well constructed, not advanced merely to agitate some readers to satisfy some perplexing thirst for social engagement.
Hope that helps. |
I've got a Aston Martin vantage But I've absolutely NO idea who put the engineer in |
Well make sure you stay out of the revenue department ! And try not to give them any advice ! |
They are clearly good friends with Illumina. They can roll out researchers to make it seem that Illumina snd AGL are commercially closer than they are. I have a rellie who works in sequencing for Illumina and they have never heard of AGL but they are in the revenue part of the business. |
Edit: with, not wuthering |
No it isn't and despite your massive ego and all seeing future prediction skills you are a clueless tw.t like most who.come.on here saying....placing.We have funding until early 2026 and deals wuthering AZ, Illumina, Eisai and outside shot but may hear news soon, Menarini |
Can't you read Januarys RNS Bobath ??They have over 12 million uk pounds Not dollars like your post insinuates Typical fraudster behaviour He was that clever at that He ends up in jail Money laundered when buying a house in Italy Told the judge his relative would pay the polio society back 41 k But didn't tell him , he'd bought property in Italy with his ill gotten gains Watch this space !! |
No one needs your baseless placing sh.t either. All u do is say placing. We agreed that you would turn over a new leaf |
Every year for the last decade this test/topic on this company has been brought up on here ...It's like the Truman show It's like comparing apples and pears !! |
Wonder he will use Parsortix @Andrew Newland
Tom Bird, professor of hepatobiliary cancer at the University of Edinburgh, who secured funding after unsuccessful attempts to win bids from three other major funders. His was the first award given in the field of oncology.
There will be a clinical study funded by the Sir Jules Thorn Charitable Trust as part of the award. This will come in two parts: first, using prospectively enrolled patients in a blood biomarker study; the second will be a subfraction of those patients and engaging them in imaging to detect these biomarkers. What we aim to do is match their liquid biopsies in the blood and their imaging features with the pathology that we’ll see when their tumours are treated. |
Toffeeman,
Just to add to my 27541, the article below focuses on use of liquid biopsy for screening of healthy people and this is what they have to say about Trucheck:-
'Another company, Datar genetics, also offer liquid biopsy screening test to otherwise healthy people. Their test is called “Trucheck”, and some GPs are offering this test in private practices in London.
The Trucheck test being offered by Datar genetics is less well studied than the Grail/Galleri test and Datar have failed to provide adequate information to reassure most doctors of its usability. Oncologists and geneticists raise what we see as highly valid questions on Datar’s datasets and the conclusions drawn from them ' |
They are using the Trucheck test developed by an Indian company called Datar Cancer Genetics. Think it's an antibody based system and looks like private clinics are offering it as well as MRI scans to screen for cancer. Seems like not everybody is on board. |
I'm confused! If they are not using Parsortix, what are they using?!
If they are using Parsotix - how come, given that it is only (as far as the company says) suitable for research.
If they are using something else - what and does it have clearance for diagnostic purposes? |
There are lots of labs that do tests. The one you quote above, use the Trublood one (not sure if they use Parsortix or not) and only test for limited cancers. Note cost £1450. NB they can do it because it's in an accredited lab. 10 day turnaround.
hxxps://www. thecancerscreeningtrust.co.uk/trublood-solid-organ |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
